The difference effect about low-dose rituximab between autoimmune nodopathy and membranous nephropathy, and the treatment regimen for nephrotic involvement in patients with anti-CNTN1 antibody need to be further explored. The gene discussed is CNTN1; the disease is membranous glomerulonephritis.